High baseline Tie1 level predicts poor survival in metastatic breast cancer
|Author:||Tiainen, Leena1,2; Korhonen, Emilia A.3; Leppänen, Veli-Matti3;|
1Department of Oncology, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, P.O. Box 100, FI-33014, Tampere, Finland
2Department of Oncology, Tampere University Hospital, P.O. Box 2000, FI-33521, Tampere, Finland
3Wihuri Research Institute and Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, P.O. Box 63, FI-00014, Helsinki, Finland
4Research, Development and Innovation Centre, Tampere University Hospital and Faculty of Medicine and Health Technology, Tampere University, P.O. Box 2000, FI-33521, Tampere, Finland
5The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, P.O. Box 100, FI-33014, Tampere, Finland
6Department of Oncology and Radiotherapy, Turku University Central Hospital, P.O. Box 52, 20521, Turku, Finland
7Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 10, 90029 OYS, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 1.3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020042019300
|Publish Date:|| 2020-04-20
Background: Angiopoietin growth factors (Angs) regulate angiogenesis and lymphangiogenesis by binding to the endothelial Tie2 receptor. Ang2 expression is elevated in tissue hypoxia and inflammation, which also induce cleavage of the extracellular domain of the orphan Tie1 receptor. Here we have examined if the concentrations of Ang2 and the soluble extracellular domain of Tie1 in patient plasma are associated with the prognosis of patients with metastatic breast cancer.
Methods: Plasma Tie1 and Ang2 levels were measured in metastatic breast cancer patients treated in a phase II trial with a taxane-bevacizumab combination chemotherapy in the first-line treatment setting. They were analyzed before treatment, after 6 weeks and 6 months of treatment, and at the final study visit. Using the median concentrations as cutoffs, Tie1 and Ang2 data were dichotomized into low and high concentration groups. Additionally, we analyzed Tie1 concentrations in plasma from 10 healthy women participating in a breast cancer primary prevention study.
Results: Plasma samples were available from 58 (89%) of the 65 patients treated in the trial. The baseline Tie1 levels of the healthy controls were significantly lower than those of the metastatic patients (p < 0.001). The overall survival of the patients with a high baseline Tie1 level was significantly shorter (multivariate HR 3.07, 95% CI 1.39–6.79, p = 0.005). Additionally, the progression-free survival was shorter for patients with a high baseline Tie1 level (multivariate HR 3.78, 95% CI 1.57–9.09, p = 0.003). In contrast, the baseline Ang2 levels had no prognostic impact in a multivariate Cox proportional hazard regression analysis. The combined analysis of baseline Tie1 and Ang2 levels revealed that patients with both high Tie1 and high Ang2 baseline levels had a significantly shorter overall survival than the patients with low baseline levels of both markers (multivariate HR for overall survival 4.32, 95% CI 1.44–12.94, p = 0.009).
Conclusions: This is the first study to demonstrate the prognostic value of baseline Tie1 plasma concentration in patients with metastatic breast cancer. Combined with the results of the Ang2 analyses, the patients with both high Tie1 and Ang2 levels before treatment had the poorest survival.
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This work was funded by the Pirkanmaa Hospital District Science Center and Seppo Nieminen funds (LT, PLKL), the Sigrid Juselius Foundation (KA), the Cancer Society of Finland (KA) and the Orion Research Foundation (EAK). Ang2 analysis was supported financially by Roche Inc. (PLKL). The design of the study, collection, analysis and interpretation of the data was done solely by the authors. The authors were also exclusively responsible for writing the manuscript.
© The Author(s). 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.